



Case report

Mycobacterium chimaera infection masquerading as a lung mass in a healthcare worker

Christian I. Rosero^{1,*}, Wael E. Shams^{2,3}

¹ Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, United States

² Department of Internal Medicine, Division of Infectious Diseases, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, United States

³ James H Quillen Veterans Affairs Medical Center, Mountain Home, TN 37684, United States

ARTICLE INFO

Article history:

Received 3 March 2019

Received in revised form 16 March 2019

Accepted 17 March 2019

ABSTRACT

Mycobacterium chimaera, a nontuberculous mycobacterium, is a member of the *Mycobacterium avium* complex (MAC). This microorganism has recently gained significant notoriety for its association with outbreaks in patients exposed to contaminated heater–cooler devices used during open heart surgeries.

We report a case of *Mycobacterium chimaera* pulmonary infection in a healthcare worker who presented with cough, low grade fever and weight loss with evidence of a lung mass that was initially thought to be a tumor on CT scan imaging. The patient underwent partial left lung lobectomy and pathology revealed necrotizing granulomas with acid fast bacilli and a culture grew *M. chimaera*. The patient received combination antimycobacterial therapy according to susceptibility results for twelve months with complete resolution of his symptoms and radiographic findings.

Infection Control investigation could not find a source of infection in the hospital where he worked during the last ten years. However, the patient rotated in different hospitals before coming to work at this facility and assisted in surgeries in several operating rooms where the heater-cooler devices in question were used.

© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Case report

A 66-year-old Caucasian male Physician Assistant was evaluated at the Infectious Disease clinic for ten-pound weight loss and worsening dry cough without fevers, night sweats or hemoptysis. He had a history of controlled type 2 diabetes mellitus, hypertension, dyslipidemia and remote history of latent tuberculosis treated in 1973 with 6 months of isoniazid. He smoked one pack of cigarettes per day during his early adulthood and quit smoking more than 40 years ago. On examination, he appeared weak and anxious with a weight 83 kg that appeared appropriate for his 185-cm height. He had a normal respiratory rate of 16 per minute, pulse of 78 per minute, and a blood pressure of 127/76 mmHg. Chest auscultation revealed good breath sounds with few left upper lobe rhonchi without crackles. The remainder of his exam was normal. Laboratory work-up revealed a white blood cell count of 5600/mm³, with 53.2% neutrophils, 29.2% lymphocytes, 11.9% monocytes, 3.8% eosinophils, hemoglobin 14.3 g/dL and platelet count 219,000/mm³ [3]. The

comprehensive metabolic panel was within normal limits and his HIV 1/2 antibody screen was negative.

Chest CT scan showed left upper lung lobe mass measuring 3.1 × 2.6 × 2.2 cm with smaller lower lobe lung nodules and mild left hilar adenopathy (Fig. 1). PET scan followed with findings concerning for malignancy. However, CT guided FNA biopsy was done and showed no evidence of malignant cells with negative routine, fungal and mycobacterial cultures. The patient was referred to cardiothoracic surgery and underwent thoracotomy and partial lobectomy with resection of the lung mass. Pathology exam revealed necrotizing granuloma with acid fast bacilli (Fig. 2).

Mycobacterial culture grew *Mycobacterium chimaera*. Confirmation and susceptibility testing were completed at the National Jewish Medical Center Mycobacteriology Laboratory in Denver, CO with molecular probes using 16S rDNA sequencing and rpoB sequencing. The isolate showed susceptibility/intermediate susceptibility to clarithromycin, rifabutin and ethambutol with minimum inhibitory concentrations of 4 mcg/mL, 0.5 mcg/mL and 8mcg/mL, respectively. It showed resistance to ciprofloxacin, moxifloxacin, linezolid and amikacin with minimum inhibitory concentrations of 16 mcg/mL, 4 mcg/mL, 64 mcg/mL and 16mcg/mL, respectively.

* Corresponding author.

E-mail address: christian.rosero18@gmail.com (C.I. Rosero).




Fig. 1. Initial CT scan of the chest showing left lung mass (arrow), nodules and hilar adenopathy (arrowheads).

The patient was initially treated with a 3-drug regimen including Rifabutin, Clarithromycin and Ethambutol. He had gastrointestinal intolerance to Clarithromycin, and it had to be switched to Azithromycin after 2 months. He also developed an allergic reaction to Rifabutin 6 months into therapy in the form of drug fever and eosinophilia and the drug had to be stopped. He completed the remaining 12 months of antimycobacterial therapy with Azithromycin and Ethambutol with complete resolution of his clinical and radiologic manifestations.

Discussion

The development of more advanced and specialized molecular techniques for identification of previously unrecognized organisms has permitted the isolation of many nontuberculous mycobacteria (NTM) as human pathogens. Additionally, there has been an increasing understanding of the defects in lung structure and immune response that facilitates these infections [1]. *Mycobacterium chimaera* (*M. chimaera*) is a slow-growing acid-fast bacillus that forms unpigmented colonies. It was first isolated in 2004 as a unique subspecies pathogen from the *Mycobacterium avium* complex (MAC) that also includes *Mycobacterium avium* and *Mycobacterium intracellulare* among others [2]. Utilization of molecular probes with 16S rDNA sequencing and rpoB sequencing is essential to identify *M. chimaera* among other members of the *Mycobacterium avium* complex [6,10].

Interest in *M. chimaera* infectious potential has emerged in the recent few years as cardiac, pulmonary and disseminated infections have been reported in patients with a history of different types of cardiac surgeries. The source of infection has

been identified to be LivaNova PLC (formerly Sorin Group Deutschland GmbH) Stöckert 3T heater-cooler devices, used during many of these surgeries. Some of these devices are thought to have been contaminated during manufacturing. *M. chimaera* was isolated from the water tanks within these heater-cooler devices [3–5]. Droplets loaded with *M. chimaera* are ejected from the contaminated water tanks within these devices, spreading an infective bioaerosol with a particle size of $< 1 \mu\text{m}$ in the operating room environment. These aerosolized droplets may be inhaled by the patient or staff and they may also settle on surfaces forming biofilms in the operating room environment or in the patients having surgeries that involve placement of prosthetic material such as heart valves or vascular grafts [5,6,13–15].

M. chimaera growth and disease in patients are slow. Marra et al reviewed 52 patients who developed *M. chimaera* infection complicating cardiovascular surgeries. They identified a period from exposure to clinical presentation up to 6 years. Patients may present with nonspecific systemic symptoms such as fatigue, fever, sweats, and weight loss. Pulmonary symptoms include chronic cough and dyspnea [16]. Tissue specimens submitted for pathology exam usually reveal noncaseating granulomas that are rarely acid-fast bacilli smear-positive [17]. Patients may develop pulmonary infection, locally invasive infection with involvement of sternal wounds, mediastinum, and pleural space, prosthetic valve infection with endocarditis, vascular graft infection, or disseminated infection with involvement of the liver, spleen, kidneys, joints, bones and bone marrow [3–6]. Patients with prosthetic valve infection and disseminated infection may have increased mortality up to 50% [3,7,8,11].

The American Thoracic Society (ATS) and the Infectious Disease Society of America (IDSA), recommend combination antimycobacterial therapy with clarithromycin, rifampin and ethambutol for patients with disseminated *Mycobacterium avium* complex infection [9]. Specific treatment regimens for patients with *M. chimaera* infection have not been recommended and will need to be outlined based on future clinical outcomes. As with other *Mycobacterium avium* complex species, *M. chimaera* infection is usually treated with a prolonged course of Clarithromycin, Ethambutol, and Rifampin. Severe disease may require additional antibiotic therapy with aminoglycosides [12].

Our patient likely contracted his *M. chimaera* in healthcare facilities where he rotated and worked in their operating rooms prior to being recruited in our facility. During his ten-year work history at our facility, he provided patient care in a pre-operative clinic without attending any operating rooms. Furthermore, our facility has not provided open heart surgeries and never carried above named heater-cooler devices that are potentially contaminated. However, we verified that the other facilities where the patient worked in their operating rooms before ten years provided open heart surgeries and used the heater-cooler devices in question.





Fig. 2. Left; Lung Mass Tissue Biopsy with H&E stain showing necrotizing granuloma is present on a fibrotic background. Right; Lung Mass Tissue Biopsy with AFB stain, showing Acid fast bacilli present within scattered histiocytes.

To our knowledge, this is the first case report of *M. chimaera* in a healthcare worker with a long incubation period reflecting the nature of *M. chimaera* slow growth and documenting *M. chimaera* as potential etiology of disease in healthcare workers exposed to bioaerosols emitted from contaminated Heater-Cooler devices during open heart surgery.

Author statement

Christian Rosero, MD: Investigation, Writing- original draft
Wael Shams, MD: Writing- Reviewing and Editing, Supervision

Conflicts of interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Acknowledgments

The authors would like to thank Dr. Gregory A. Stancel and Laura E Stewart, from Highlands Pathology Consultants, P.C. Blountville, TN. 37617, for generously providing the pathology images for this article.

References

- [1] Sexton P, Harrison AC. Susceptibility to nontuberculous mycobacterial lung disease. *Eur Respir J* 2008;31:1322–33, doi:http://dx.doi.org/10.1183/09031936.00140007.
- [2] Tortoli E, Rindi L, Garcia MJ, Chiaradonna P, Dei R, Garzelli C, et al. Proposal to elevate the genetic variant MAC-A included in the *Mycobacterium avium* complex, to species rank as *Mycobacterium chimaera* sp. *Nov. Int J Syst Evol Microbiol* 2004;54:1277–85, doi:http://dx.doi.org/10.1099/ijs.0.02777-0.
- [3] Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, et al. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated *Mycobacterium chimaera* infections subsequent to open heart surgery. *Eur Heart J* 2015;36:2745–53, doi:http://dx.doi.org/10.1093/eurheartj/ehv342.
- [4] Scriven JE, Scobie A, Verlander NQ, Houston A, Collyns T, Cajic V, et al. *Mycobacterium chimaera* infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases. *Clin Microbiol Infect* 2018;24:1164–70, doi:http://dx.doi.org/10.1016/j.cmi.2018.04.027.
- [5] Sommerstein R, Rüegg C, Kohler P, Bloemberg G, Kuster SP, Sax H. Transmission of *Mycobacterium chimaera* from heater-cooler units during cardiac surgery despite an ultraclean air ventilation system. *Emerg Infect Dis* 2016;22:1008–13, doi:http://dx.doi.org/10.3201/eid2206.160045.
- [6] Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, et al. Prolonged outbreak of mycobacterium chimaera infection after open-chest heart surgery. *Clin Infect Dis* 2015, doi:http://dx.doi.org/10.1093/cid/civ198.
- [7] Bills ND, Hinrichs SH, Aden TA, Wickert RS, Iwen PC. Molecular identification of *Mycobacterium chimaera* as a cause of infection in a patient with chronic obstructive pulmonary disease. *Diagn Microbiol Infect Dis* 2009, doi:http://dx.doi.org/10.1016/j.diagmicrobio.2008.12.002.
- [8] Moutsoglou DM, Merritt F, Cumberler E. Disseminated *Mycobacterium chimaera* presenting as vertebral osteomyelitis. *Case Rep Infect Dis* 2017, doi:http://dx.doi.org/10.1155/2017/9893743.
- [9] Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007, doi:http://dx.doi.org/10.1164/rccm.200604-571ST.
- [10] Lecorche E, Haenn S, Mougari F, Kumanski S, Veziris N, Benmansour H, et al. Comparison of methods available for identification of *Mycobacterium chimaera*. *Clin Microbiol Infect* 2018, doi:http://dx.doi.org/10.1016/j.cmi.2017.07.031.
- [11] Achermann Y, Rössle M, Hoffmann M, Deggim V, Kuster S, Zimmermann DR, et al. Prosthetic valve endocarditis and bloodstream infection due to *Mycobacterium chimaera*. *J Clin Microbiol* 2013, doi:http://dx.doi.org/10.1128/JCM.00435-13.
- [12] Moon SM, Kim SY, Jhun BW, Lee H, Park HY, Jeon K, et al. Clinical characteristics and treatment outcomes of pulmonary disease caused by *Mycobacterium chimaera*. *Diagn Microbiol Infect Dis* 2016, doi:http://dx.doi.org/10.1016/j.diagmicrobio.2016.09.016.
- [13] Chand M, Lamagni T, Kranzer K, Hedge J, Moore G, Parks S, et al. Insidious risk of severe mycobacterium chimaera infection in cardiac surgery patients. *Clin Infect Dis* 2017, doi:http://dx.doi.org/10.1093/cid/ciw754.
- [14] Götting T, Klassen S, Jonas D, Benk C, Serr A, Wagner D, et al. Heater-cooler units: contamination of crucial devices in cardiothoracic surgery. *J Hosp Infect* 2016, doi:http://dx.doi.org/10.1016/j.jhin.2016.02.006.
- [15] Haller S, Höller C, Jacobshagen A, Hamouda O, Abu Sin M, Monnet DL, et al. Contamination during production of heater-cooler units by *Mycobacterium chimaera* potential cause for invasive cardiovascular infections: results of an outbreak investigation in Germany, April 2015 to February 2016. *Eurosurveillance* 2016, doi:http://dx.doi.org/10.2807/1560-7917.ES.2016.21.17.30215.
- [16] Marra AR, Diekema DJ, Edmond MB. *Mycobacterium chimaera* infections associated with contaminated heater-cooler devices for cardiac surgery: outbreak management. *Clin Infect Dis* 2017;65:669–74, doi:http://dx.doi.org/10.1093/cid/cix368.
- [17] Ben Appenheimer A, Diekema DJ, Berriel-Cass D, Crook T, Daley CL, Dobbie D, et al. *Mycobacterium chimaera* outbreak response: experience from four US healthcare systems IDWeek. 2016.